Acura Accused Of Securities Fraud Over Acurox

Law360, New York (September 15, 2010, 3:35 PM EDT) -- A shareholder has launched a putative class action against Acura Pharmaceuticals Inc., accusing the pharmaceutical research company of misleading investors about the ability of its lead product, the painkiller Acurox, to deter abuse as a result of its niacin content.

Named plaintiff Chris Bang's complaint, lodged Friday in the U.S. District Court for the Northern District of Illinois, claims the company knew the U.S. Food and Drug Administration had doubts about the drug, which contains the narcotic oxycodone and the supplement niacin, but did not contain...
To view the full article, register now.